サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1703310

薬剤耐性てんかん市場- 世界の産業規模、シェア、動向、機会、予測、治療タイプ別、エンドユーザー別、地域別、競合市場別、2020-2030F

Drug-Resistant Epilepsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By End User, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 184 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

薬剤耐性てんかん市場- 世界の産業規模、シェア、動向、機会、予測、治療タイプ別、エンドユーザー別、地域別、競合市場別、2020-2030F
出版日: 2025年04月11日
発行: TechSci Research
ページ情報: 英文 184 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

薬剤耐性てんかんの世界市場規模は2024年に18億5,000万米ドル、2030年には24億4,000万米ドルに達すると予測され、予測期間中の年間平均成長率（CAGR）は4.72％を記録します。

同市場は、従来の抗てんかん薬（AED）では十分な効果が得られない患者のアンメットニーズへの対応に焦点を当てた強力な研究開発活動により、進化を続けています。

市場概要
予測期間 2026-2030
市場規模：2024年 18億5,000万米ドル
市場規模：2030年 24億4,000万米ドル
CAGR：2025年～2030年 4.72%
急成長セグメント 神経調節療法
最大市場 北米

てんかんは、発作の再発を特徴とする神経疾患で、世界的に多くの患者が罹患しています。薬剤耐性てんかん-難治性てんかんとも呼ばれる-は、2種類以上の適切なAEDによる治療にもかかわらず発作が続く症例を指します。難治性てんかんはアンメット・メディカル・ニーズの高い疾患であり、世界の市場において技術革新と投資が進んでいます。

主な市場促進要因

てんかん有病率の増加

主な市場課題

複雑かつ不均一な疾患プロファイル

主要市場動向

神経画像技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の薬剤耐性てんかん市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 治療の種類別（神経調節療法、抗てんかん薬、ベンゾジアゼピン、てんかん切除手術、特定の代謝治療、特定の遺伝子治療、免疫療法）
    • エンドユーザー別（病院・診療所、外来診療センター、その他）
    • 地域別
    • 企業別（2024）
  • 市場マップ
    • 治療の種類別
    • エンドユーザー別
    • 地域別

第5章 アジア太平洋地域の薬剤耐性てんかん市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 治療の種類別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • オーストラリア
    • 日本
    • 韓国

第6章 欧州の薬剤耐性てんかん市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • 英国

第7章 北米の薬剤耐性てんかん市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第8章 南米の薬剤耐性てんかん市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第9章 中東・アフリカの薬剤耐性てんかん市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第10章 市場力学

  • 促進要因
  • 課題

第11章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第12章 世界の薬剤耐性てんかん市場：SWOT分析

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • UCB S.A.
  • Jazz Pharmaceuticals
  • LivaNova PLC
  • NeuroPace, Inc
  • Avenue Therapeutics
  • Xenon Pharmaceuticals Inc.
  • Marinus Pharmaceuticals
  • PTC Therapeutics
  • Aquestive Therapeutics
  • Neuroelectrics

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 16867

Global Drug-Resistant epilepsy market was valued at USD 1.85 billion in 2024 and is projected to reach USD 2.44 billion by 2030, registering a compound annual growth rate (CAGR) of 4.72% during the forecast period. This market continues to evolve, driven by robust research and development activities focused on addressing the unmet needs of patients who exhibit inadequate response to conventional anti-epileptic drugs (AEDs).

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.85 Billion
Market Size 2030USD 2.44 Billion
CAGR 2025-20304.72%
Fastest Growing SegmentNeuromodulation Therapy
Largest MarketNorth America

Epilepsy, a neurological condition characterized by recurrent seizures, affects a significant global population. Drug-resistant epilepsy-also known as refractory epilepsy-refers to cases in which patients continue to experience seizures despite treatment with two or more appropriate AEDs. This segment represents a substantial unmet clinical need, propelling innovation and investment across the global market landscape.

Key Market Drivers

Increasing Prevalence of Epilepsy

The rising global incidence of epilepsy is a primary factor fueling market growth. According to the World Health Organization (WHO), approximately 50 million individuals worldwide are affected by epilepsy. Of this population, an estimated 30% do not respond adequately to standard anti-seizure therapies, resulting in drug-resistant forms of the disorder.

As global demographics shift toward an aging population, the overall prevalence of epilepsy is expected to rise, contributing to an increased burden of drug-resistant cases. This trend underscores the urgent need for advanced therapeutic solutions tailored to this difficult-to-treat patient group.

Additionally, while up to 70% of epilepsy patients could potentially achieve seizure control with appropriate treatment, approximately 75% of individuals in low-income regions lack access to essential medications. This treatment gap highlights the critical importance of early diagnosis, improved access to care, and continued innovation in therapeutic options designed specifically for drug-resistant epilepsy.

Key Market Challenges

Complex and Heterogeneous Disease Profile

One of the most significant challenges in treating drug-resistant epilepsy is the condition's complex and heterogeneous nature. The disorder comprises a wide range of seizure types, each with distinct etiologies, clinical presentations, and treatment responses. This variability complicates efforts to develop universally effective therapies.

The evolving nature of drug-resistant epilepsy further contributes to its clinical complexity. Seizure patterns and drug efficacy may change over time, requiring continuous reassessment and adaptation of treatment strategies. As a result, the development of standardized interventions remains a major hurdle, necessitating a more personalized approach to care.

Key Market Trends

Advancements in Neuroimaging Technologies

Innovations in neuroimaging are significantly enhancing diagnostic and therapeutic capabilities in the drug-resistant epilepsy market. These advanced imaging techniques are transforming clinical approaches by providing deeper insights into brain structure and function.

Modern Magnetic Resonance Imaging (MRI) technologies-including functional MRI (fMRI), diffusion tensor imaging (DTI), and magnetic resonance spectroscopy (MRS)-offer high-resolution views of brain activity, connectivity, and subtle structural abnormalities. These tools are instrumental in identifying epileptic foci and guiding surgical or targeted treatment options.

Positron Emission Tomography (PET) also plays a crucial role by detecting metabolic irregularities in brain regions associated with seizure activity. Enhanced by advanced radiotracers and image processing methods, PET imaging facilitates more accurate diagnosis and localization of epileptic zones.

In addition, Single-Photon Emission Computed Tomography (SPECT) is widely used to assess cerebral blood flow during seizures, helping clinicians pinpoint seizure origins and inform personalized treatment planning. Collectively, these advancements are fostering a more precise and effective management paradigm for drug-resistant epilepsy.

Key Market Players

  • UCB S.A.
  • Jazz Pharmaceuticals
  • LivaNova PLC
  • NeuroPace, Inc
  • Avenue Therapeutics
  • Xenon Pharmaceuticals Inc.
  • Marinus Pharmaceuticals
  • PTC Therapeutics
  • Aquestive Therapeutics
  • Neuroelectrics

Report Scope:

In this report, the Global Drug-Resistant Epilepsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Drug-Resistant Epilepsy Market, By Treatment Type:

  • Neuromodulation Therapy
  • Antiseizure Medications
  • Benzodiazepines
  • Resective Epilepsy Surgery
  • Specific Metabolic Treatment
  • Specific Genetic Treatment
  • Immunotherapy

Drug-Resistant Epilepsy Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Drug-Resistant Epilepsy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Drug-Resistant Epilepsy Market.

Available Customizations:

Global Drug-Resistant Epilepsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Drug-Resistant Epilepsy Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Treatment Type (Neuromodulation Therapy, Antiseizure Medications, Benzodiazepines, Resective Epilepsy Surgery, Specific Metabolic Treatment, Specific Genetic Treatment, Immunotherapy)
    • 4.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 4.2.3. By Region
    • 4.2.4. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Treatment Type
    • 4.3.2. By End User
    • 4.3.3. By Region

5. Asia Pacific Drug-Resistant Epilepsy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type
    • 5.2.2. By End User
    • 5.2.3. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Drug-Resistant Epilepsy Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Treatment Type
        • 5.3.1.2.2. By End User
    • 5.3.2. India Drug-Resistant Epilepsy Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Treatment Type
        • 5.3.2.2.2. By End User
    • 5.3.3. Australia Drug-Resistant Epilepsy Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Treatment Type
        • 5.3.3.2.2. By End User
    • 5.3.4. Japan Drug-Resistant Epilepsy Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Treatment Type
        • 5.3.4.2.2. By End User
    • 5.3.5. South Korea Drug-Resistant Epilepsy Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Treatment Type
        • 5.3.5.2.2. By End User

6. Europe Drug-Resistant Epilepsy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Drug-Resistant Epilepsy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Germany Drug-Resistant Epilepsy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Spain Drug-Resistant Epilepsy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By End User
    • 6.3.4. Italy Drug-Resistant Epilepsy Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Treatment Type
        • 6.3.4.2.2. By End User
    • 6.3.5. United Kingdom Drug-Resistant Epilepsy Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Treatment Type
        • 6.3.5.2.2. By End User

7. North America Drug-Resistant Epilepsy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Drug-Resistant Epilepsy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By End User
    • 7.3.2. Mexico Drug-Resistant Epilepsy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By End User
    • 7.3.3. Canada Drug-Resistant Epilepsy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By End User

8. South America Drug-Resistant Epilepsy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Drug-Resistant Epilepsy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By End User
    • 8.3.2. Argentina Drug-Resistant Epilepsy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Colombia Drug-Resistant Epilepsy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By End User

9. Middle East and Africa Drug-Resistant Epilepsy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Drug-Resistant Epilepsy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By End User
    • 9.3.2. Saudi Arabia Drug-Resistant Epilepsy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By End User
    • 9.3.3. UAE Drug-Resistant Epilepsy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By End User

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Drug-Resistant Epilepsy Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. UCB S.A.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Jazz Pharmaceuticals
  • 14.3. LivaNova PLC
  • 14.4. NeuroPace, Inc
  • 14.5. Avenue Therapeutics
  • 14.6. Xenon Pharmaceuticals Inc.
  • 14.7. Marinus Pharmaceuticals
  • 14.8. PTC Therapeutics
  • 14.9. Aquestive Therapeutics
  • 14.10. Neuroelectrics

15. Strategic Recommendations

16. About Us & Disclaimer